

## UBS Global I/O

### Tech Hardware & Semis

#### 1Q20 UBS APAC Tech Tour: Key takeaways

##### COVID-19 overrides discussions; China improving, more uncertainty elsewhere

We "virtually" met with over 25 companies in the tech supply chain in China, Taiwan, Korea and Japan. COVID-19 dominated the discussions. 1/ Overall production in China looks to be slowly getting back on track, with EMS/downstream production back to c. 85-100% of expected seasonal levels (pre demand adjustments) by end March. 2/ end-demand in China is starting to recover in March after a dismal February. 3/ end-demand uncertainty outside of China is evidently growing by the day, with the supply chain and OEMs struggling to assess it at this stage.

##### Smartphones & PC demand downside, hyperscale servers demand holding firm

We lower our smartphone industry unit estimates to -5% YoY in 2020 (was +1%), whilst keeping 2021 units largely unchanged. We also revise down our 5G smartphone units forecast for 2020 to 223mil from 275mil before. The China domestic smartphones market is improving from a very low base as offline retail re-opens & channel inventories slowly come down. We would expect the iPhone SE2 ramp schedule to be pushed out into April (still c. 30mil procurement target). However, while travel ban poses additional difficulties for Apple in getting the components qualified, we do not think this is enough for now to change the product launch schedule for iPhone 12 series in Sep '20. PC demand is also impacted, although lowered production means Intel CPU bottleneck is at this point not an issue anymore. Hyperscale servers demand is the one bright spot, with continuing strength from most large US customers, and some recent acceleration from Chinese customers.

##### Lag in semis orders adjustment, upside to memory pricing continues though

Feedback from the foundries and fabless companies are that demand forecasts have not come down. With that said, our view is customers were unwilling to cut given the foundry tightness, but with a significant change in end demand, the cuts are a matter of time. We are therefore pre-emptively lowering our estimates on TSMC ([link](#)) and MediaTek ([link](#)). Post re-assessing memory supply / demand though ([link](#)), we increase our memory pricing forecasts. We forecast 2Q20 DRAM contract pricing to increase 10% QoQ (server DRAM >20%) and NAND flash 3% QoQ.

##### Risk/reward for tech improving post correction

For full Most/ Least Prefs globally see Page 2.

#### Equities

Global

Technology

##### Nicolas Gaudois

Analyst

nicolas.gaudois@ubs.com  
+852-2971 5681

##### Taewoo Lee

Analyst

taewoo.lee@ubs.com  
+852-2971 6873

##### Bill Lu

Analyst

bill.lu@ubs.com  
+852-2971 8360

##### Timothy Arcuri

Analyst

timothy.arcuri@ubs.com  
+1-415-352 5676

##### Thompson Wu

Analyst

thompson.wu@ubs.com  
+886-28-722 7338

##### Kenji Yasui

Analyst

kenji.yasui@ubs.com  
+81-3-5208 6211

##### David Mulholland, CFA

Analyst

david.mulholland@ubs.com  
+44-20-7568 4069

##### Alice Chen

Analyst

alice.chen@ubs.com  
+886-2-8722 7343

##### Shingo Hirata, CFA

Analyst

shingo.hirata@ubs.com  
+81-3-5208 6224

##### William Dong

Analyst

william.dong@ubs.com  
+886-2-8722 7338

##### Jimmy Yu

Analyst

S1460517080002  
jimmy.yu@ubssecurities.com  
+86-213-866 8880

##### Sunny Lin

Analyst

sunny.lin@ubs.com  
+886-2-8722 7346

**Figure 1: UBS Tech Most/Least preferred list**

Company	Ticker	Rating	Price	PT	'20E PE	'21E PE	'20E PB	'21E PB	'20E EV/Sales	'21E EV/Sales
<b>Most preferred</b>										
Apple	AAPL.O	Buy	US\$277.97	US\$335	21.1	17.6	20.66	35.19	3.98	3.60
Catcher	2474.TW	Buy	NT\$187	NT\$255	8.2	6.9	0.92	0.85	1.78	1.61
GUC	3443.TW	Buy	NT\$181.5	NT\$300	18.5	14.2	4.84	4.27	1.67	1.38
Infineon	IFXGn.DE	Buy	€14.084	€24.5	16.0	13.8	1.90	1.74	1.89	1.66
Intel	INTC.O	Buy	US\$54.43	US\$75	11.0	10.7	2.92	2.70	3.66	3.57
Lens Tech	300433.SZ	Buy	Rmb16.02	Rmb23.5	23.9	19.4	2.87	2.55	2.09	1.75
Marvell	MRVL.O	Buy	US\$20.78	US\$28	35.8	22.7	1.84	1.59	4.76	3.63
MediaTek	2454.TW	Buy	NT\$320	NT\$430	18.3	15.7	1.64	1.58	1.29	1.13
Murata Mfg.	6981.T	Buy	¥4817	¥7000	14.0	12.4	1.70	1.55	1.85	1.65
NVIDIA	NVDA.O	Buy	US\$240.84	US\$320	31.0	27.3	9.10	10.82	9.50	9.99
Samsung Electronics	005930.KS	Buy	Won48900	Won74000	11.5	8.3	1.25	1.13	0.91	0.83
Samsung SDI	006400.KS	Buy	Won253000	Won330000	20.5	14.1	1.35	1.23	1.02	0.86
SEMCO	009150.KS	Buy	Won103000	Won140000	15.6	9.6	1.37	1.21	1.07	0.89
Sony	6758.T	Buy	¥5633	¥9100	11.3	10.2	1.44	1.27	-0.69	-0.73
TDK	6762.T	Buy	¥7810	¥13200	9.6	7.7	1.01	0.91	0.70	0.62
TSMC	2330.TW	Buy	NT\$276.5	NT\$380	16.9	14.4	4.10	3.65	5.58	4.84
Universal Scientific	601231.SS	Buy	Rmb18.09	Rmb23	23.1	16.2	3.61	3.07	0.84	0.66
<b>Least preferred</b>										
Applied Materials	AMAT.O	Sell (CBE)	US\$50.89	US\$51	12.9	12.3	5.24	5.31	3.35	3.16
Chipbond	6147.TWO	Sell	NT\$53.6	NT\$51	9.8	10.3	1.13	1.07	1.42	1.36
GoerTeK	002241.SZ	Sell	Rmb17.23	Rmb12	36.2	29.5	3.51	3.18	1.08	0.81
Hirose Electric	6806.T	Sell	¥9190	¥11500	19.4	18.4	1.09	1.06	0.98	0.94
LG Display	034220.KS	Neutral	Won10800	Won11500	-11.4	10.9	0.37	0.36	0.54	0.54
O-Film Tech	002456.SZ	Sell	Rmb14.59	Rmb11.7	35.1	23.7	4.23	3.65	1.14	1.00
Pegatron	4938.TW	Sell	NT\$52.6	NT\$50	13.2	12.6	0.90	0.86	0.09	0.08
Sanan Opto	600703.SS	Sell	Rmb22.8	Rmb14.5	50.3	40.8	4.23	3.92	11.46	9.92
Sharp	6753.T	Sell	¥958	¥910	9.0	9.3	1.50	1.32	0.33	0.32
SMIC	0981.HK	Sell (CBE)	US\$12	US\$10	-94.5	430.9	0.98	0.97	2.65	2.59
Texas Instruments	TXN.O	Sell (UR)	US\$106.04	US\$117	19.7	16.6	11.19	10.66	6.99	6.27
Wistron	3231.TW	Sell	NT\$22.15	NT\$17	13.5	13.4	0.74	0.71	0.10	0.10

Source: UBS estimates, price as of 16<sup>th</sup> March 2020 for Asia stocks, 13<sup>th</sup> March 2020 for US and Europe stocks.

# 每日免费获取报告

1. 每日微信群内分享**7+**最新重磅报告；
2. 定期分享**华尔街日报**、**金融时报**、**经济学人**；
3. 和群成员**切磋交流**，对接优质合作资源；
4. 累计解锁**8万+**行业报告/案例，**7000+**工具/模板

申明：行业报告均为公开版，权利归原作者所有，小编整理自互联网，仅分发做内部学习。

手机用户建议先截屏本页，微信扫一扫

或搜索公众号“**尖峰报告**”

回复<进群>，加入每日报告分享微信群

限时领取“2020行业资料大礼包”，关注即可获得



# 1Q20 APAC Tech Tour takeaways

## COVID19 update from the supply chain

Coronavirus impact to the supply dominated the discussions throughout all the meetings. **1/ Overall production in China looks to be slowly getting back on track. 2/ end-demand in China is starting to recover in March after a dismal February. 3/ end-demand uncertainty outside of China is evidently growing by the day, with the supply chain and OEMs struggling to assess it at this stage.**

### Supply impact: slowly recovering from the disruption

Post Chinese New Year we started to see the Coronavirus impact to China production materializing meaningfully, with some of the key challenges coming from disruptions in logistics, labour resources, as well as the inspection capacity from the government for production resumption. At the current stage we believe most of the supply chain is in the process of normalizing, but the pace varying depending mainly on 1) labour intensity and 2) priority in getting the government approval to resume (largely determined by the scale of the business).

- **Upstream:** So far we think the impact for overall semis manufacturing looks very limited, with the processes being more automated and the fabs typically operating in a more controlled environment. Accordingly, we believe there has been limited disruption to semis production for existing capacity. Samsung is facing some delays in installing new capacity in Xi'an (NAND) but this appears limited to 3-4 weeks. SK Hynix has some delays in bringing engineers on site to calibrate equipment in both Wuxi (DRAM) and its Korean sites, but we believe the impact is fairly limited. YMTC (NAND) being in Wuhan is facing the airport shutdown with equipment stranded in airport and not moving in, until of course the situation normalises. Display production overall has seen a relatively more direct impact, mainly due to some of the production sites being located within Wuhan (Tianma, CSOT, BOE B17) and bottlenecks from the module side. While overall order adjustments for 1Q20 so far have been minimal, a shared concern from the upstream suppliers is the demand downside which could start to fully materialize into 2Q20.
- **Downstream:** Impact has been more visible for EMS and ODM companies, with the nature of the business being more labour intensive and the utilization rate having come down sharply due to shortage in labours post CNY. Labour bottlenecks are slowly starting to be resolved, and Hon Hai targets to return to for full production recovery by end of March. Similarly, while resumption in progress, server rack assembly presents bottleneck for server production for the OEM/ODMs. The effort to normalize the labour shortage in urgency will likely incur additional costs such as additional incentives paid and logistics and transportation support provided to the returning workers, some of which to be partially shared with the customers and the government. There are still some pending issues to be resolved, such as components sourcing from smaller suppliers (or suppliers of suppliers), some of which are still pending government inspection and approval for production resumption.

**Figure 2: COVID-19 production recovery status overview**

Company	UBS view on the production status
ASPEED	ODMs labour looks fine; CPU remains tight; foundry capacity also tight
Catcher	3 production sites in China back to operating, but labour challenging; trying to recover UR
Foxconn Industrial	Production 50% end-Feb and to be normalized by end-Mar
Hon Hai	Labour recovery 50% early-Mar and full recovery by end-Mar; potential shortage in components
Lenovo	Overall UR 85% but production lower due to supply chain bottlenecks; smartphone production site in Wuhan partially open but UR very low
LG Display	Limited operational impact; potential shortages in components; seeing delays for China OLED fab ramp due to engineers
LG Electronics	China production resuming operation at 80-90% capacity; presents limited impact to overall production
Mediatek	No bottleneck for production so far
Partron	No impact and no issues in sourcing materials/components, supply chain mostly in Vietnam
Samsung	No impact to production; seeing some delays in new capacity additions due to equipment installation (c. 3-4 weeks for Xi'an – NAND)
SK Hynix	No impact to production; potential issues could be China logistics; delays in capacity additions due to equipment installation
Telling	40% of its offline stores open in Feb; >90% of its stores open in Mar
Tokyo Electron	Logistics disrupted for YMTC orders delivery and installation; some difficulties in sending engineers for other China production sites but minor
TSMC	No impact to production; downstream supply chain disrupted in Feb and recovering
Win Semi	No impact to production; Win Semi's supply chain concentrated to Taiwan
Xiaomi	Smartphone assembly has come back to normal level; CMOS image sensors remain tight

Source: UBS

## Demand impact: likely inevitable with growing concerns

We see the end-demand impact as being inevitable and presenting a bigger concern for the supply chain. While we think the demand loss could lead to more pent-up demand and to be recouped later on for enterprise-related products, we believe that for consumer products this will extend the product cycle and lead to demand loss for the full year. Demand in China evidently took a hit in February, but has now started to recover. The biggest issue is that OEMs and the supply chain struggle to be ahead of / quantify possible demand downside outside of China for 2H March and 2Q20 at least.

- **China smartphones OEMs:** More than 50% of the offline distribution stores in China were closed in Feb; this is now coming back in Mar and planning for full recovery by April. However, a growing concern is demand for overseas market.
- **Apple:** Apple suspended its guidance for 1CQ20 ([link](#)), iPhone China units in Feb were down 61% YoY ([link](#)), and we think risk still persists with demand potentially at risk beyond China. We also think the production disruptions observed suggest that the upcoming iPhone SE2 ramp schedule will likely be pushed out into April. However, while travel ban poses additional difficulties for Apple in getting the components qualified, with the supply chain slowly recovering and there being enough time still, we do not think this is enough to change the product launch schedule for iPhone 12 series in Sep 2020.
- **PCs:** Production disruption in China has hindered the ability for PC OEM/ODM to deliver shipment to their customers. Lenovo notes China PCs market likely being down 30% YoY for 1Q20. Based on our supply chain analysis, we estimate Taiwan NB ODM shipment to decline by 45%

QoQ in Q1, lower than historical range of 14%-23% QoQ decline over the past 5 years. While the production challenges should gradually alleviate into 2Q, end-demand remains the key uncertainty ahead as consumption and corporate spending might not recover to previous levels in the short-term.

- **Servers:** Despite some bottlenecks in the production supply chain, server demand so far looks relatively unscathed from COVID impact compared to other segments of the market, with some upsides even from select customers. Enterprise demand is seeing negative impact due to COVID disruptions, especially for China enterprise. On the other hand, hyperscale-related demand is largely unchanged into 2Q20 as well as for the full year, with some upside from some of the tier 2 China hyperscale customers.

## Smartphones: lowering estimates

**We revise down our global smartphone unit forecast to -5% YoY from +1% for 2020 as we reflect the downside to end-demand from COVID-19.**

We are mainly lowering estimates for 1H20, and while we assume some of the lost demand to be partially made up in 2H, our view is that not of this will be recouped as we will see product refresh cycle being simply pushed out.

By OEMs, most of our downward revision comes from disruptions in China (for both production and end-demand) and therefore from China smartphone OEMs. We believe the China domestic smartphones market was already facing excess channel inventories, notably pre CNY. February demand then turned out to be particularly weak, with CAICT China smartphone shipment data for February indicating -55% YoY. Since then, our checks indicate an improvement in demand in the first week of March. One large distributor indicated smartphones inventories coming down vs prior 2 weeks, with more velocity so far for iPhone vs Android. We expect China smartphones demand to continue to recover from here.

Unfortunately the COVID-19 demand-related risks are now moving to Europe and shortly after the rest of the world. OEMs are therefore expecting downside into 2Q20 but obviously struggle to quantify those, hence why the supply chain is not yet identifying those in full.

- **Apple:** We adjusted our forecasts post initial supply chain disruption and February China sales ([link](#)). The supply chain is now calibrated for an April release of the SE2, and volumes still close to 30mil procurement in 2020. In spite of disruptions in the qualification process for the supply chain, we believe there is time for enough normalisation for the iPhone 12 to meet its initial 2H20 launch calendar.
- **Samsung:** We lower our Samsung smartphones unit Sell In ests further to 276m (-6.5% YoY) from 285mil prior. We believe 1Q20 is coming in close to 64mil (was 66.5mil) with some downside in GS20 units (9mil), although with a mix more biased towards the Ultra. The Flip could reach 250k Sell In in 1Q, but is slightly supply-constrained to the disruption in temporary production at Gumi post COVID-19. We have factored in some downside to global demand (notably Europe) in 2Q20 and forecast 67mil smartphones Sell In.
- **Huawei:** We revise down our procurement estimate to 210mil (-12.5% YoY) from 250mil for 2020. This comes from (1) initial excess channel inventories

entering CNY in the China domestic market (c. 10mil); (2) COVID-19 production and demand impact in China since; (2) possible further downside to Europe demand in 2Q20. We have not factored in yet risks related to possible changes in US Entity List rules ([link](#)). We also note that further downside to non-China demand could come from limitations in users experience imposed by no license for Google application services.

- **Xiaomi:** We recently tuned down our 2020 smartphones forecasts ([link](#)) and forecast 128mil units Sell In in 2020. Smartphones assembly is pretty much back to normal at this point. On the demand side, volumes are gradually coming back in China after a severe negative impact in February. So far demand overseas has held up but evidently uncertainty is building up, notably in Southern Europe where Xiaomi has solid market share.
- **Oppo/Vivo:** We forecast smartphones procurement close of 107/103mil for both respectively in 2020. Again this may not fully appreciate the downside to China demand into 2Q20.
- **LGE:** We lower our forecast further to 27.4mil (-5.5mil YoY) smartphones units Sell In in 2020 (was 28.1mil). LGE is over-indexed to Americas demand, and COVID-19 demand impact may take a bit longer to filter through.
- **Lenovo:** We could see further downside to our forecasts, notably due to supply. 50% of smartphones production is in China, and Wuhan is the main site.

**Figure 3: UBS Global smartphone shipment forecast changes**

	New			Old			% change		
	2019	2020E	2021E	2019E	2020E	2021E	2019E	2020E	2021E
Global smartphone units	1,371	1,303	1,355	1,345	1,359	1,372	1.9%	-4.1%	-1.3%
% YoY	-2.2%	-5.0%	4.0%	-2.0%	1.0%	1.0%			

Source: Company data, UBS estimates

**Figure 4: UBS Global smartphone shipment by OEMs**

(mil units)	2018	2019	1Q20E	2Q20E	3Q20E	4Q20E	2020E	1Q21E	2Q21E	3Q21E	4Q21E	2021E
Samsung	290.0	295.0	64.0	67.0	75.7	69.0	275.7	64.5	71.5	75.5	63.5	275.0
% of total	20.7%	21.5%	23.1%	23.3%	22.6%	17.1%	21.2%	21.0%	23.7%	22.1%	15.7%	20.3%
% YoY	-8.2%	1.7%	-11.1%	-11.8%	-3.0%	0.0%	-6.5%	0.8%	6.7%	-0.3%	-8.0%	-0.3%
Huawei*	206.0	240.8	48.0	50.0	57.0	55.0	210.0	55.0	55.0	62.0	58.0	230.0
% of total	14.7%	17.6%	17.3%	17.4%	17.0%	13.6%	16.1%	17.9%	18.2%	18.1%	14.4%	17.0%
% YoY	34.6%	16.9%	-18.8%	-14.8%	-14.7%	-2.1%	-12.8%	14.6%	10.0%	8.8%	5.5%	9.5%
Apple	204.4	193.0	40.0	37.0	44.0	74.0	195.0	49.0	41.0	46.0	74.7	210.7
% of total	14.6%	14.1%	14.4%	12.9%	13.1%	18.3%	15.0%	15.9%	13.6%	13.5%	18.5%	15.6%
% YoY	-5.3%	-5.6%	-8.0%	1.4%	2.3%	5.7%	1.0%	22.5%	10.8%	4.5%	1.0%	8.1%
Xiaomi	118.7	123.1	25.3	29.1	36.4	37.2	128.1	32.2	31.3	39.1	38.2	140.8
% of total	8.5%	9.0%	9.2%	10.1%	10.9%	9.2%	9.8%	10.5%	10.4%	11.4%	9.4%	10.4%
% YoY	29.9%	3.7%	-9.2%	-9.5%	13.5%	20.1%	4.0%	26.8%	7.8%	7.3%	2.6%	9.9%
OPPO*	113.3	112.8	20.0	25.0	32.0	30.0	107.0	26.0	28.0	30.0	28.0	112.0
% of total	8.1%	8.2%	7.2%	8.7%	9.6%	7.4%	8.2%	8.5%	9.3%	8.8%	6.9%	8.3%
% YoY	1.6%	-0.4%	-13.4%	-15.3%	2.6%	3.4%	-5.1%	30.0%	12.0%	-6.3%	-6.7%	4.7%
Vivo*	105.0	100.5	21.0	25.0	29.0	28.0	103.0	26.0	28.0	28.0	26.0	108.0
% of total	7.5%	7.3%	7.6%	8.7%	8.7%	6.9%	7.9%	8.5%	9.3%	8.2%	6.4%	8.0%
% YoY	5.4%	-4.3%	-9.5%	-12.0%	5.5%	30.8%	2.5%	23.8%	12.0%	-3.4%	-7.1%	4.9%
Lenovo	39.4	37.5	7.6	9.4	9.7	8.6	35.3	8.5	9.3	9.3	8.4	35.5
% of total	2.8%	2.7%	2.7%	3.3%	2.9%	2.1%	2.7%	0.7%	0.7%	0.7%	0.6%	2.7%
% YoY	-16.8%	-4.9%	-21.1%	-0.5%	-0.1%	-1.1%	-5.8%	11.8%	-1.1%	-4.1%	-2.3%	0.6%
LG Electronics	39.5	29.0	6.9	6.7	7.3	6.5	27.4	6.6	6.4	7.0	6.2	26.3
% of total	2.8%	2.1%	2.5%	2.3%	2.2%	1.6%	2.1%	2.2%	2.1%	2.1%	1.5%	1.9%
% YoY	-29.1%	-26.6%	-8.0%	-6.9%	-2.7%	-4.4%	-5.5%	-4.0%	-4.0%	-4.0%	-4.0%	-4.0%
Others	285.7	239.5	44.1	38.0	43.8	95.2	221.1	39.6	31.0	44.8	101.1	216.4
% of total	20.4%	17.5%	15.9%	13.2%	13.1%	23.6%	17.0%	12.9%	10.3%	13.1%	25.0%	16.0%
% YoY	-3.6%	-16.2%	-2.5%	-15.2%	-11.5%	-4.7%	-7.7%	-10.1%	-18.5%	2.1%	6.1%	-2.1%
Total volumes	1,402.0	1,371.2	276.9	287.2	335.0	403.6	1,302.6	307.4	301.6	341.7	404.1	1,354.7
% YoY	1.1%	-2.2%	-11.0%	-11.0%	-3.0%	2.9%	-5.0%	11.0%	5.0%	2.0%	0.1%	4.0%

Source: Company data, UBS estimates; \*procurement estimates for non-covered companies shown

## Revising down 5G smartphone forecasts

Within our global smartphone unit revision, we also **revise down our global 5G smartphone unit forecast for 2020 to 223mil from 275mil before**, and for 2021 to 453mil from 500mil before. Most of the revision comes from Huawei and other China smartphone OEMs. We also adjust down our Samsung 5G units to 36mil from 45mil before, due to weaker than expected demand for Galaxy S20 series, and Galaxy Z Flip coming without 5G support. Our Apple iPhone forecast for 5G is unchanged as we do not think the disruptions so far is enough to change the product launch schedule for iPhone 12 series in Sep 2020.



**Figure 5: UBS Global 5G smartphone shipment forecasts**

(mil units)	2019	2020E	2021E
Apple	0	65	140
Samsung	7	36	93
Huawei	7	48	84
Xiaomi	1	15	35
LGE	1	3	7
Other Android	3	56	94
<b>Total 5G smartphones</b>	<b>19</b>	<b>223</b>	<b>453</b>
<i>% of total smartphones</i>	<i>1%</i>	<i>17%</i>	<i>33%</i>

Source: Company data, UBS estimates

## PCs

**Considering COVID-19 risks, we lower our global PC shipment forecast for 2020E to -4.2% YoY from -1.3% ([link](#)).**

With the outbreak of COVID-19, the first impact to global PC industry is production disruption in China. This has hindered the ability for PC OEM/ODM to deliver shipment to their customers. For Q2, as workers gradually return to factories in China, we believe PC OEM/ODMs are in process of bringing their production back online. However, for production to resume to full capacity, we would still need all key segments within the supply chain to normalize, from raw material to components to assembly. Looking ahead, we expect production to eventually resume to full capacity and compensate for the production shortfall in Q1 and Q2.

One silver lining in reduced production rates is that the availability of Intel's CPUs – which turned into a more serious issue late 4Q19 – is now not a bottleneck for the larger PC OEMs. We believe those are offered incremental procurement volumes from CPU vendors.

Key uncertainty ahead is the impact of COVID-19 outbreak on PC end demand as consumption and corporate spending might not recover to previous levels in the short-term. This comes in addition to the Windows 10 replacement cycle on the corporate side slowing down post Win7 extended support termination last January.

## Servers

**Robust servers procurement from hyperscale customers has continued YTD.**

We forecast servers unit procurement from hyperscale customers to grow 15.9% YoY in 2020 ('19E: -9.0%). We see continuing procurement strength from most US hyperscalers. Recently, we have seen some upside in orders from Chinese customers, including OEMs, although customers have been facing some logistical challenges with COVID-19 (assembly, but also installation on sites).

The supply chain expects strength from hyperscale procurement to continue in 2Q20. On the flipside, enterprise demand remains more anaemic for now. Intel's Ice Lake processors availability in volumes to customers continues to be expected by the supply chain for 1H21.

## Memory Semis

We updated our supply / demand model post the Tour, indicating DRAM moderate undersupply til 3Q21 vs. NAND gradually coming back to some oversupply in 4Q20/2021 ([link](#)). We up our memory pricing forecasts & in the near term forecast blended DRAM contract prices up 10% QoQ (was +6%) in 2Q20 & NAND +3% (was flat).

We believe that the recovery in hyperscale server DRAM procurement has continued for most US large customers, and has recently accelerated across Chinese customers (although COVID-19 present logistical challenges). In the near term, we believe this is pushing server DRAM contract pricing up >20% QoQ in 2Q20 with 32GB server DRAM pricing towards US\$140-150. For NAND flash, solid state drive storage and flash arrays for servers is also robust.

Mobile DRAM and embedded NAND flash demand are seeing some modest downward adjustments in procurement and will ultimately be more negatively affected by COVID-19. On the flipside, this may set the stage for a robust recovery into 2021.

COVID-19 is not having any impact on memory production so far. This is however leading to up c. 3-4 weeks delay in equipment installation at Samsung's Xi'an X2 (NAND flash), and YMTC (NAND) not being able to move in new equipment (as the fab is in Wuhan). More importantly though, we believe demand uncertainty related to COVID-19 is leading Samsung to put on pause possible plans for upsized capacity ramp for 2020 at both Xi'an (NAND) and P2 (DRAM). We hence maintain our prior forecasts of Samsung to add 55k wpm gross capacity in NAND in '20, 40k wpm in DRAM, and for SK Hynix, 20k wpm in NAND and 10k wpm in DRAM.

## Foundry

We met with TSMC and also discussed foundry plans with Samsung. Overall the feedback is foundries have not seen any downside from COVID-19: No disruptions on the supply side, and although demand downside into Q2/Q3 seems likely to us, it is too early to quantify.

Our view is capex plans are likely on track, as both TSMC and Samsung are expanding 5nm and 7nm. However, we do believe TSMC's capex is front-end loaded. Geopolitical tension and the potential for additional CPU businesses are key issues raised by investors, and our view is eventually TSMC could build a U.S. fab: 1) geopolitical tension and U.S. customers' desire to increase U.S. content, 2) the desire to stay ahead of competitors on Moore's Law and therefore the need to recruit U.S. engineers, and 3) concerns about Taiwan's electricity and other utilities. In the near-term, our view on foundry competition is unchanged. We do see Samsung taking some share at 7nm this year (Qualcomm and NVIDIA), but we are not seeing any other customer movements.

## Displays

### Large panel LCD

We updated our supply / demand model ([link](#)) indicating some large panels LCD undersupply continuing, but fading down, for most of 2021. We now forecast LCD TV panels pricing to increase 10% QoQ in 1Q20, and 6% increase in 2Q.

With more production sites being located in China, LCD panel production has seen more disruptions due to Coronavirus than other upstream tech. While negative impact to end-consumption become more visible into 2Q, we think this is for now leading to tighter supply and LCD TV panel price increase accelerating. We think the persisting issues could be sourcing of some of the smaller components as well as labour resources for the back-end module processes.

So far the panel makers have seen relatively limited order adjustments for 1Q20, but considering China market being 23% of global TV units, we believe this is simply a matter of time. Furthermore we are increasingly more concerned on the demand risk potentially widening to other markets beyond China. Furthermore, once China production fully normalizes and new capacity ramps resume, we expect China supply growth to return its trajectory and lead to global area supply growth.

## Large panel OLED

Following the initial challenges in 2H19 ([link](#)), we believe Coronavirus is further delaying LG Display's China Guangzhou OLED gen 9.5 (TV panels) fab ramp schedule, as engineers cannot come in back / forth from Korea. We believe the fab is now targeting final equipment tuning by end-Mar to start production ramp from Apr onward to reach 60k spm capacity by end of 2Q20. We think the further delay in ramp presents downside risks to the targeted OLED TV panel unit of ~6mil for 2020 and alongside possible COVID-19 demand impact, forecast 5.3mil OLED TV panel units shipments in 2020 ([link](#)).

We believe Samsung is so far on track for its ramp-up of QD Display (OLED TV panels) production. We estimate Samsung has closed down ~110k spm of its LCD capacity on Korea in 2H19, and has placed most of the equipment orders need to convert this into 30k spm QD Display capacity. Our expectation on the timeline for commercial QD Display TV product remains unchanged with early 2021 products announcements (CES 2021 very likely in our view). Beyond, we think Samsung remains committed to its plan to convert away all of its remaining LCD capacity in Korea (Line 8) over the next several years. So far we do not have any visibility on the timing of potential gen 10.5 QD Display capacity. Regarding the recent industry discussions on Samsung adopting "QNED" technology for its next generation TV products, our view is that this is still at its early stage and multiple years away from being a commercially viable solution.

## Mobile OLED

**Samsung:** The supply chain's visibility on the timing of Samsung A5 investment remains low. However, we believe that the upcoming display changes for iPhones in 2021 will lead to capacity loss in A3, and this supplemented by demand increase will likely lead to Samsung A5 capacity addition. We expect iPhones to change its display technology to use LTPO OLED from 2021, which will enable ~10% power efficiency gain, a necessity for more 5G mmWave volumes ([link](#)). The shift of existing LTPS OLED lines to LTPO, combined with the ongoing changes to accommodate for Y-OCTA adoption this year, will lead to reduction in Samsung's existing capacity from the conversion. We believe the capacity reduction, paired with stable demand improvement, firms up the visibility for Samsung A5 investment, and we are more confident that Samsung will need to add capacity for output by 2H21, implying equipment orders should start from 2H20 (likely towards end-2020) ([link](#)).

**LG Display:** After finally getting into Apple OLED supply chain in 2H19, we expect LG Display to increase its OLED volume towards Apple meaningfully this year. In addition to the legacy model, we expect LG Display to supply one of the 2H20 new OLED models as well, and we estimate this could increase the company's full year iPhone OLED volume to ~15-20mil. From capacity perspective, so far LG Display has only been utilizing 1 line (15k spm) from its E6 fab, and from 2H20 expect the company to operate both lines (30k spm total) to support the volume increase.

**China OLED:** Some of the ongoing capacity ramp-up plans are seeing delays, due to difficulties in getting the engineers support for the final equipment installation. Separately for equipment orders though, after close to a year of quietness, we started to see OLED equipment orders from Chinese panel makers recover aggressively from 2H19 (with GVO, CSOT, and Tianma). For the nearer term this could be maintained until equipment orders for BOE B12 fully follow through within 1H20. Beyond this, however, we expect the Chinese panel makers to enter a digestion phase to for all the capacity they have committed to installing so far, and order momentum to taper off. While there are still some new projects left in the longer term plan such as BOE B15 and CSOT T5, the numbers are coming down and these remain at a far too early stage.

- **BOE:** the latest B11 fab is close to being fully installed with total 48k capacity. The next project from BOE is the B12 fab, for which after some delays from the initial supply chain expectation, we recently started to see equipment purchase orders materializing from Feb for all three lines (delivery likely to be in sequence per line, 1 line each in 2H20/1Q21/2H21 respectively). Once B12 is fully equipped, BOE will then have in total 144k spm gen 6 OLED capacity installed. The next planned project would be B15 fab, but the current supply chain discussions suggest this might not be until 2021/22 at the earliest.
- **China Star (CSOT):** T4 fab capacity addition is ongoing - the last phase of equipment orders were finally placed in early Jan, with delivery scheduled for Oct 2020. We think the next fab T5 is present in the longer term company plan, but again still at a very initial stage and far out.
- **Visionox (GVO):** front end equipment orders were placed in Sep for 30k, with delivery scheduled for Nov 2020. Beyond this we do not see any new fab projects in sight. V2 fab still has one more production line to fill, but visibility in the supply chain remains low.
- **Tianma:** Wuhan fab is currently adding phase 2 (15k), with equipment orders starting from 4Q19. Initial stage discussions for a new production line in Xiamen are emerging, but with no expectation on timeline.

**Figure 6: Mobile OLED capacity forecasts**

(k spm)	Gen	2016	2017	2018	2019	2020E	2021E
<b>Samsung Display</b>							
SDI A1	4	55	55	55	55	55	55
A2	5.5	158	178	190	190	190	190
A3	6	26	98	135	135	124	109
A4	6	--	4	30	30	30	30
A5	6			--	--	--	19
<b>LG Display</b>							
E2	4	14	14	14	14	14	14
E5	6	--	11	15	15	15	15
E6	6		--	8	20	30	30
<b>BOE</b>							
Chengdu B7	6	--	8	16	48	48	48
Mianyang B11	6		--	--	20	44	48
Chongqing B12	6			--	--	4	32
Fuzhou B15	6			--	--	--	4
<b>Visionox</b>							
Kunshan V1	5.5	4	4	4	4	4	4
Gu'an V2	6		--	4	15	15	15
Hefei V3	6		--	--	--	4	30
<b>Tianma</b>							
TNM Shanghai AMOLED 2	5.5	2	4	4	4	4	4
TNM Zouling Wuhan AMOLED	6		--	15	15	15	30
<b>CSOT</b>							
Wuhan T4 OLED	6		--	--	8	23	45
<b>Others</b>							
Ever Display Shanghai 1	4	8	9	10	11	12	12
Ever Display Shanghai 2 LTPS	6			--	--	8	15
Truly Huizhoi B AMOLED	4.5	5	15	15	15	15	15
Royole OLED	5.5		--	1	5	15	15
JDI Mobara J1 AMOLED	4.5				8	8	8
Sharp AMOLED Sakai MP+Pilot	4.5			8	8	8	8
AUO L4B AMOLED	H4	8	8	8	8	8	8
<b>Total installed OLED capacity (gen 6 eq, k spm)</b>		<b>162</b>	<b>274</b>	<b>388</b>	<b>476</b>	<b>536</b>	<b>647</b>
<b>% YoY</b>			<b>69.1%</b>	<b>41.6%</b>	<b>22.6%</b>	<b>12.7%</b>	<b>20.8%</b>

Source: Company data, IHS, UBS estimates

# APPENDIX

Figure 7: UBS Global PC shipment forecasts

(mil units)		2014	2015	2016	2017	2018	2019	2020E	2021E
<i>By product segment</i>									
Desktops		133.6	118.2	108	102.3	99.8	100.3	96.2	95.5
	% YoY	-1.7%	-11.5%	-8.7%	-5.3%	-2.4%	0.5%	-4.1%	-0.7%
Notebooks		180.1	169.5	162.2	160.4	160	162.3	154	155.7
	% YoY	-0.2%	-5.9%	-4.3%	-1.1%	-0.2%	1.4%	-5.1%	1.2%
Total PC		313.7	287.7	270.1	262.7	259.8	262.6	250.2	251.2
	% YoY	-0.8%	-8.3%	-6.1%	-2.7%	-1.1%	1.1%	-4.7%	0.4%
Chromebooks		5.7	6.8	9.4	12.8	14.9	16	16.6	16.9
	% YoY	111.9%	18.8%	38.2%	35.7%	16.7%	7.4%	3.9%	1.4%
Total Units		319.4	294.5	279.5	275.4	274.7	278.6	266.8	268.1
	% YoY	0.1%	-7.8%	-5.1%	-1.5%	-0.3%	1.4%	-4.2%	0.5%
<i>By end-application</i>									
Commercial PC		165.3	156.1	156.2	164.3	168.8	180.2	173.9	175.7
	% YoY	-2.5%	-5.6%	0.1%	5.2%	2.7%	6.7%	-3.5%	1.0%
Consumer PC		154.2	138.4	123.3	111.1	105.9	98.4	92.9	92.4
	% YoY	3.2%	-10.2%	-10.9%	-9.9%	-4.7%	-7.0%	-5.7%	-0.5%
Total Units		319.4	294.5	279.5	275.4	274.7	278.6	266.8	268.1
	% YoY	0.1%	-7.8%	-5.1%	-1.5%	-0.3%	1.4%	-4.2%	0.5%

Source: Gartner, UBS estimates

**Figure 8: What are companies saying about the supply chain?**

---

### **Corporates are extremely uncertain about the impact**

Adelaide Brighton (25 Feb): "It's too early to really judge the impacts"

ASE Technology (7 Feb): "Supply chain risk is also troublesome and extremely difficult for us to evaluate"

Balkrishna Industries (17 Feb): "It's too early to say"

Caltex (24 Feb): "It is still too early to assess the full impact of the coronavirus"

City Development (25 Feb): "The full impact on businesses, operations and supply chains is still unknown"

Hitachi (31 Jan): "if the supply chain is cut then it will have an impact. We are concerned about this impact but we cannot quantify or incorporate this in our forecast yet"

Honda Motor (7 Feb): "we cannot say when the production stops"

Hua Hong Semis (14 Feb): "it's going to eventually affect us, okay, in the supply chain. I don't know when this is going to happen"

Inari Amertron (25 Feb): "The impact of COVID-19 on global growth and global supply chain is hard to assess at this stage"

LG Display (31 Jan): "it should have an impact, both on the supply and the demand. However, given the uncertainties surrounding this issue, I believe that the uncertainties are greater on the supply side"

Nissan Motor (13 Feb): "supply chain disruptions... still uncertain at this time"

Olympus (6 Feb): "the impact of the coronavirus outbreak is very hard to predict"

Siam Cement (29 Jan): "Negative impact from Coronavirus outbreak is needed to be monitored"

Sime Darby (26 Feb): "The impact of the coronavirus outbreak cannot be accurately estimated at this juncture"

Tata Chemicals (3 Feb): "We haven't yet assessed the supply chain knock-on impacts of the Chinese coronavirus"

Tata Motors (30 Jan): "not able to get visibility of what the situation on the ground is with respect to not just the demand, but also the extended supply chain"

Yamaha Motor (13 Feb): "still uncertain at this time"

### **Some evidence of supply chain issues is already apparent / expected imminently**

Alumina (24 Feb): "there are supply chain disruptions in China affecting bauxite, alumina, aluminium and other raw material flows. This has resulted in a spike in the API as China imports more alumina to satisfy smelter production needs"

Appen (25 Feb): "Some of our US customers rely on China for their hardware supply chain and have signaled supply challenges"

Bluescope Steel (23 Feb): "you just can't get trucks to deliver your products. So I suspect there's going to be a backlog in the supply chain for a period of time that it is really difficult for us to forecast... it is expected that February and March business performance will be heavily impacted"

Hap Seng (26 Feb): "the COVID-19 outbreak could negatively impact [the Trading division's] supply chain. Building Materials Division's operations via MMSB and Hafaryare expected to be affected by supply disruptions"

Honda (7 Feb): "the impact to Automobile business is much higher... usually, we have 3 days inventory"

Minebea Mitsumi (5 Feb): "We cannot imagine any fan products without any components from China. So we believe there will be some impact"

Motherson Sumi (10 Feb): "some suppliers have issued force majeure letters in North America and in some other regions"

Olympus (6 Feb): "supply chain would be constrained as well, obviously. So we don't know to what extent we can actually deliver the product"

Sembcorp Marine (20 Feb): "Challenges remain, in particular supply chain disruptions due to the COVID-19 virus outbreak, which could affect execution of Marine projects"

Shen Siong (20 Feb): "There appear to be some disruptions to the supply chain...and this will raise input prices and may affect the Group's gross margin if these increases cannot be passed on to the customers"

Sime Darby (26 Feb): "the disruptions to vehicle and equipment supply chains may also affect sales in other countries"

Singapore Technologies Engineering (23 Feb): "customer demand reduction, supply chain and workforce redistribution. For example, if airlines continue to scale back their flight schedule, it will affect our aerospace MRO business as more airline customers adjust or delay maintenance cycle"

### **But most believe that issues will only become apparent if supply chain disruptions continue**

Bharat Forge (10 Feb): "30% of the global supply chain for manufactured goods comes out of China and about 20% of manufacturers goods are purchased by China. So if you put a stop on it for 30 to 45 days, it's quite a big impact"

Blue Star (31 Jan): "We have sufficient raw material and finished goods to cater to the overall supplies that are needed to fulfil sales for quarter 4"

Glenmark Pharma (17 Feb): "This quarter, we are covered. Q4, we are covered, and part of Q1, we are covered. After that, it will all depend on how things evolve in China"

IPCA Laboratories (13 Feb): "supply has to start coming somewhere between mid-March, so that your main production is not hampered"

Lenovo (20 Feb): "I think we have enough components to ensure a couple of weeks production"

Lupin (6 Feb): "Based on the inventories and what we have in WIP, we don't see a disruption in this quarter. If the situation sorts out in the next few weeks... we don't see an issue"

Mahindra & Mahindra (11 Feb): "We have 1 component coming from China, and that affects approximately 3,000 to 3,500 vehicles of BS IV, total effect. We are hoping that it will open up in a week to 10 days. If that happens, then we'll be able to still manage, time-wise. If it goes beyond, let's say, February end, it will become very difficult"

Natco Pharma (13 Feb): "this phenomenon will have an impact on the earnings, if the supply chain problems continue in the near term"

Nikon Corp (6 Feb): "if the problem is to continue a lot longer, we particularly have to pay attention to our FPD Systems Business and Imaging Business"

Rio Tinto (26 Feb): "prepared for some short-term impacts, such as supply-chain issues. Our products are currently reaching our customers"

Softbank (7 Feb): "both handsets and base stations, I think we have enough inventory built up to be able to deal with the situation, at least for the short term. But if this prolongs for 3 months, 6 months, then there may be some impact one way or another. I think it'd be the handsets. Perhaps that will be the case when there's that big March sales season, we could be impacted"

Viva Energy (23 Feb): "this has not yet had a material impact on operations or financial results, however could do so in the event of substantial expansion of the issue"

Voltas (10 Feb): "While we are adequately covered for the quarter 4, certain alternate sources of supply can and will be pressed into action"

Wesfarmers (19 Feb): "Longer term into the first half of next year, if it drags on, there would be some stuff we'd have to look at around some of the seasonal products"

---

### Efforts are being made to try to minimise the impact

Adelaide Brighton (25 Feb): "Our strategy is to keep our stock levels high at this point in time... There is an ability, albeit less efficient, to increase the capacity of production in some of our aged plants should we fall into a situation where importation is a challenge"

Bluescope Steel (23 Feb): "shipping products around or finding other suppliers"

Delta (17 Feb) "will take the necessary measures to ensure that our supply chain remains resilient, including the close collaboration between our procurement department and its suppliers"

Honda Motor (7 Feb): "we may change the order of the production so that we can continue the operation of the production line"

Hyundai Motors (7 Feb): "Countermeasures for work stoppage include increasing supply from domestic and SE Asian suppliers, and minimising supply lead time when vendors located in China resume their operation."

Nippon Yusen (31 Jan): "agilely responding through adjustments to the capacity supply"

Nissan Motor (13 Feb) "the alternative parts and supplementary parts and components, we have a plan and we have put into implementation"

Reliance Worldwide Corp (23 Feb): "The company is working actively with its supply partners to prioritise production to restock products that have lower inventory levels"

Shen Siong (20 Feb): "The Group is increasing its level of inventory in view of the uncertainties in the supply chain"

Volta (10 Feb): "While we are adequately covered for the quarter 4, certain alternate sources of supply can and will be pressed into action"

### Some businesses (or parts of businesses) believe they are well placed to withstand the challenges

Breville (12 Feb): "for unrelated reasons, Breville is holding finished goods inventory above our normal equilibrium levels"

Fonterra (26 Feb): "already contracted a high percentage of our 2020 financial year's milk supply and this is helping us manage the impact of coronavirus"

Honda Motor (7 Feb): "for the motorcycle and power products, we have very high level of inventory. So even if the production stops... the sales will not stop"

Mitsubishi Chemical (12 Feb): "there are no signs of further decline either even in the face of this coronavirus outbreak"

SATS (13 Feb): "We haven't suffered from any serious disruptions in our raw material supply chain for food"

Stockland (19 Feb): "staying very close to our retailers to understand from them... at the moment is that stocks for the following season is already landed in Australia"

Symphony (7 Feb): "most of our supplies for the coming... couple of months or 2, 3 months have already been received"

Woolworths (25 Feb): "A lot of those long-life goods, we can swing production elsewhere if we need to. And really, the fixtures are the same. So we don't feel in a bad place"

---

Source: AlphaSense, UBS

### Valuation Method and Risk Statement

Investing in the technology sector involves a high degree of risk. Rapid technological changes, increasing competition and exposure to macroeconomic cycles are among the many risks faced by investors in technology stocks. Moreover, it is extremely difficult to project the financial results of tech companies since their operating models are highly volatile and unpredictable. Finally, valuing technology stocks can prove challenging, as neither traditional nor non-traditional valuation measures have provided much insight into how these stocks trade.



## Required Disclosures

This report has been prepared by UBS Securities Asia Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit [www.ubs.com/disclosures](http://www.ubs.com/disclosures). The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 16 March 2020 06:35 PM GMT. UBS has designated certain Research department members as Derivatives Research Analysts where those department members publish research principally on the analysis of the price or market for a derivative, and provide information reasonably sufficient upon which to base a decision to enter into a derivatives transaction. Where Derivatives Research Analysts co-author research reports with Equity Research Analysts or Economists, the Derivatives Research Analyst is responsible for the derivatives investment views, forecasts, and/or recommendations.

**Analyst Certification:** Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

### UBS Investment Research: Global Equity Rating Definitions

12-Month Rating	Definition	Coverage <sup>1</sup>	IB Services <sup>2</sup>
Buy	FSR is > 6% above the MRA.	44%	32%
Neutral	FSR is between -6% and 6% of the MRA.	41%	29%
Sell	FSR is > 6% below the MRA.	15%	20%
Short-Term Rating	Definition	Coverage <sup>3</sup>	IB Services <sup>4</sup>
Buy	Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.	<1%	<1%
Sell	Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.	<1%	<1%

Source: UBS. Rating allocations are as of 31 December 2019.

1: Percentage of companies under coverage globally within the 12-month rating category.

2: Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

3: Percentage of companies under coverage globally within the Short-Term rating category.

4: Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

**KEY DEFINITIONS:** **Forecast Stock Return (FSR)** is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months. In some cases, this yield may be based on accrued dividends. **Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium). **Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case. **Equity Price Targets** have an investment horizon of 12 months.

**EXCEPTIONS AND SPECIAL CASES:**UK and European Investment Fund ratings and definitions are: **Buy:** Positive on factors such as structure, management, performance record, discount; **Neutral:** Neutral on factors such as structure, management, performance record, discount; **Sell:** Negative on factors such as structure, management, performance record, discount. **Core Banding Exceptions (CBE):** Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with FINRA. Such analysts may not be associated persons of UBS Securities LLC and therefore are not subject to the FINRA restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

**UBS AG Hong Kong Branch:** Nicolas Gaudois; Taewoo Lee. **UBS Securities LLC:** Bill Lu; Timothy Arcuri. **UBS Securities Pte. Ltd., Taipei Branch:** Thompson Wu; Alice Chen; William Dong; Sunny Lin. **UBS Securities Japan Co., Ltd.:** Kenji Yasui; Shingo Hirata, CFA. **UBS AG London Branch:** David Mulholland, CFA. **UBS Securities Co. Limited:** Jimmy Yu.

## Company Disclosures

Company Name	Reuters	12-month rating	Short-term rating	Price	Price date
<b>Advanced Process Systems Corporation</b>	265520.KQ	Neutral	N/A	Won23,200	16 Mar 2020
<b>Apple Inc.</b> <sup>7, 16b, 22</sup>	AAPL.O	Buy	N/A	US\$277.97	13 Mar 2020
<b>Applied Materials Inc</b> <sup>16b, 20</sup>	AMAT.O	Sell (CBE)	N/A	US\$50.89	13 Mar 2020
<b>ASML</b> <sup>16b</sup>	ASML.AS	Buy	N/A	€216.10	13 Mar 2020
<b>Catcher Technology</b>	2474.TW	Buy	N/A	NT\$187.00	16 Mar 2020
<b>Chipbond Technology</b>	6147.TWO	Sell	N/A	NT\$53.60	16 Mar 2020
<b>Fingerprint Cards AB</b> <sup>20</sup>	FINGb.ST	Sell (CBE)	N/A	SKr10.95	13 Mar 2020
<b>Global Unichip</b>	3443.TW	Buy	N/A	NT\$181.50	16 Mar 2020
<b>GlobalWafers</b>	6488.TWO	Neutral	N/A	NT\$322.00	16 Mar 2020
<b>GoerTek</b>	002241.SZ	Sell	N/A	Rmb17.23	16 Mar 2020
<b>Hirose Electric</b>	6806.T	Sell	N/A	¥9,190	16 Mar 2020
<b>Hitachi</b> <sup>3</sup>	6501.T	Buy	N/A	¥2,903.5	16 Mar 2020
<b>Hon Hai Precision</b>	2317.TW	Neutral	N/A	NT\$71.10	16 Mar 2020
<b>Infineon Technologies AG</b> <sup>18</sup>	IFXGn.DE	Buy	N/A	€14.08	13 Mar 2020
<b>INNOLUX Corporation</b> <sup>1, 4, 5, 7</sup>	3481.TW	Neutral	N/A	NT\$6.02	16 Mar 2020
<b>Intel Corp.</b> <sup>4, 6a, 6b, 6c, 7, 16b, 22</sup>	INTC.O	Buy	N/A	US\$54.43	13 Mar 2020
<b>KLA Corporation</b> <sup>16b</sup>	KLAC.O	Sell (UR)	N/A	US\$145.37	13 Mar 2020
<b>Lens Technology</b>	300433.SZ	Buy	N/A	Rmb16.02	16 Mar 2020
<b>LG Display</b> <sup>16b</sup>	034220.KS	Neutral	N/A	Won10,800	16 Mar 2020
<b>LG Innotek</b>	011070.KS	Neutral	N/A	Won96,500	16 Mar 2020
<b>Marvell Technology Group</b> <sup>16b</sup>	MRVL.O	Buy	N/A	US\$20.78	13 Mar 2020
<b>MediaTek Inc.</b>	2454.TW	Buy	N/A	NT\$320.00	16 Mar 2020
<b>Murata Manufacturing</b>	6981.T	Buy	N/A	¥4,817	16 Mar 2020
<b>NVIDIA Corp</b> <sup>16b, 22</sup>	NVDA.O	Buy	N/A	US\$240.84	13 Mar 2020
<b>O-Film Tech</b>	002456.SZ	Sell	N/A	Rmb14.59	16 Mar 2020

Company Name	Reuters	12-month rating	Short-term rating	Price	Price date
<b>Pegatron</b>	4938.TW	Sell	N/A	NT\$52.60	16 Mar 2020
<b>Samsung Electro-Mechanics</b>	009150.KS	Buy	N/A	Won103,000	16 Mar 2020
<b>Samsung Electronics<sup>22</sup></b>	005930.KS	Buy	N/A	Won48,900	16 Mar 2020
<b>Samsung SDI</b>	006400.KS	Buy	N/A	Won253,000	16 Mar 2020
<b>Sanan Optoelectronics</b>	600703.SS	Sell	N/A	Rmb22.80	16 Mar 2020
<b>Semiconductor Manufacturing Intl Corp<sup>2, 4, 5, 13, 16a, 20</sup></b>	0981.HK	Sell (CBE)	N/A	HK\$12.00	16 Mar 2020
<b>Sharp</b>	6753.T	Sell	N/A	¥958	16 Mar 2020
<b>Siltronic AG<sup>18</sup></b>	WAFGn.DE	Neutral	N/A	€58.36	13 Mar 2020
<b>SK Hynix</b>	000660.KS	Neutral	N/A	Won80,600	16 Mar 2020
<b>Sony<sup>7, 16b, 22</sup></b>	6758.T	Buy	N/A	¥5,633	16 Mar 2020
<b>Sunny Optical Technology<sup>4, 16a</sup></b>	2382.HK	Buy	N/A	HK\$103.30	16 Mar 2020
<b>Taiwan Semiconductor Manufacturing<sup>16b, 22</sup></b>	2330.TW	Buy	N/A	NT\$276.50	16 Mar 2020
<b>Taiyo Yuden</b>	6976.T	Buy	N/A	¥2,377	16 Mar 2020
<b>TDK</b>	6762.T	Buy	N/A	¥7,810	16 Mar 2020
<b>Texas Instruments Inc<sup>16b</sup></b>	TXN.O	Sell (UR)	N/A	US\$106.04	13 Mar 2020
<b>Universal Scientific Industrial</b>	601231.SS	Buy	N/A	Rmb18.09	16 Mar 2020
<b>Wistron Corporation</b>	3231.TW	Sell	N/A	NT\$22.15	16 Mar 2020
<b>Wonik IPS</b>	240810.KQ	Neutral	N/A	Won25,850	16 Mar 2020

Source: UBS. All prices as of local market close.

Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock pricing date

1. UBS is acting as manager/co-manager, underwriter, placement or sales agent in regard to an offering of securities of this company/entity or one of its affiliates.
2. UBS AG, its affiliates or subsidiaries has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.
3. UBS Securities Japan Co., Ltd. is acting as advisor to Hitachi, Ltd. on its acquisition announced on 12/17/2018 of Power Grids Division from ABB Ltd.
4. Within the past 12 months, UBS AG, its affiliates or subsidiaries has received compensation for investment banking services from this company/entity or one of its affiliates.
5. UBS AG, its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
- 6a. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and investment banking services are being, or have been, provided.
- 6b. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and non-investment banking securities-related services are being, or have been, provided.

- 6c. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and non-securities services are being, or have been, provided.
- 7. Within the past 12 months, UBS Securities LLC and/or its affiliates have received compensation for products and services other than investment banking services from this company/entity.
- 13. UBS AG, its affiliates or subsidiaries beneficially owned 1% or more of a class of this company's common equity securities as of last month's end (or the prior month's end if this report is dated less than 10 days after the most recent month's end).
- 16a. UBS Securities Hong Kong Limited is a market maker in the Hong Kong-listed securities of this company.
- 16b. UBS Securities LLC makes a market in the securities and/or ADRs of this company.
- 18. UBS AG London branch or affiliates acts as liquidity provider or market maker in the financial instruments of this company.
- 20. Because this security exhibits higher-than-average volatility, the FSR has been set at 15% above the MRA for a Buy rating, and at -15% below the MRA for a Sell rating (compared with 6/-6% under the normal rating system).
- 22. UBS AG, its affiliates or subsidiaries held other significant financial interests in this company/entity as of last month's end (or the prior month's end if this report is dated less than 10 working days after the most recent month's end).

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research.

Additional Prices: SUMCO, ¥1,226 (16 Mar 2020); Shin-Etsu Chemical, ¥9,139 (16 Mar 2020); Source: UBS. All prices as of local market close.

### **Company profile and fee and risk statement under the Japanese Financial Instruments & Exchange Law**

Company Name etc: UBS Securities Japan Co., Ltd., Financial Instruments & Exchange Firm, Kanto Local Financial Bureau (Kinsho) No.2633

Associated Memberships: Japan Securities Dealers' Association, the Financial Futures Association of Japan, and Type II Financial Instruments Firms Association and Japan Investment Advisers Association

UBS Securities Japan Co., Ltd. will receive a brokerage fee (excluding tax) from clients of Wealth Management calculated by multiplying the executed amount by 1.00% at maximum (excluding tax) for trading domestic stocks; and by 1.25% at maximum (excluding tax) for trading foreign stocks. However, in the case of trading other than the auction market trading such as OTC trading and Tostnet trading, a higher fee may be charged based on an individual agreement with a client. The method of fee calculation is not explained here because fee varies depending on the market condition and the content of trading, etc. From the clients of the Investment Bank, UBS Securities Japan Co., Ltd. will receive a brokerage fee based on an individual contract and no standard upper limit or calculating method. For the trading of domestic stocks, consumption tax is added to the fee. For the trading of foreign stock, fee on the foreign stock exchange or foreign tax may be charged in addition to the domestic fee and tax. Those amounts may vary depending on the jurisdiction. There is a risk that a loss may occur due to a change in the price of the stock in the case of trading stocks, and that a loss may occur due to the exchange rate in the case of trading foreign stocks. There is a risk that a loss may occur due to a change in the price or performance of the properties in the portfolio in the case of trading REITs.

UBS Securities Japan Co., Ltd. will only receive the purchasing amounts for trading unlisted bonds (JGBs, municipals, government guaranteed bonds, corporate bonds) when UBS Securities Japan Co., Ltd. is the counterparty. There is a risk that a loss may occur due to a change in the price of the bond caused by the fluctuations in the interest rates, and that a loss may occur due to the exchange rate in the case of trading foreign bonds.

# The Disclaimer relevant to Global Wealth Management clients follows the Global Disclaimer.

## Global Disclaimer

This document has been prepared by UBS Securities Asia Limited, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

**This Document is provided solely to recipients who are expressly authorized by UBS to receive it. If you are not so authorized you must immediately destroy the Document.**

Global Research is provided to our clients through UBS Neo, and in certain instances, UBS.com and any other system or distribution method specifically identified in one or more communications distributed through UBS Neo or UBS.com (each a system) as an approved means for distributing Global Research. It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

All Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the UBS Neo Platform Use Agreement (the "Neo Terms") together with any other relevant terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, you agree that use shall be subject to this Global Research Disclaimer, the Neo Terms and where applicable the UBS Investment Bank terms of business (<https://www.ubs.com/global/en/investment-bank/regulatory.html>) and to UBS's Terms of Use/Disclaimer (<http://www.ubs.com/global/en/legalinfo2/disclaimer.html>). In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<http://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<http://www.ubs.com/global/en/homepage/cookies/cookie-management.html>).

**If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, provide to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.**

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction.

This document is a general communication and is educational in nature; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. By providing this document, none of UBS or its representatives has any responsibility or authority to provide or have provided investment advice in a fiduciary capacity or otherwise. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. None of UBS or its representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. By receiving this document, the recipient acknowledges and agrees with the intended purpose described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors.

Options, structured derivative products and futures (including OTC derivatives) are not suitable for all investors. Trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a copy of "The Characteristics and Risks of Standardized Options." You may read the document at <http://www.theocc.com/publications/risks/riskchap1.jsp> or ask your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for any claims, comparisons, recommendations, statistics or other technical data will be supplied upon request. Past performance is not necessarily indicative of future results. Transaction costs may be significant in option strategies calling for multiple purchases and sales of options, such as spreads and straddles. Because of the importance of tax considerations to many options transactions, the investor considering options should consult with his/her tax advisor as to how taxes affect the outcome of contemplated options transactions.

Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Prior to making any investment or financial decisions, any recipient of this document or the information should take steps to understand the risk and return of the investment and seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and circumstances of his or her investment objectives.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any materials to which this document relates (the "Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups, personnel or other representative of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances may this document or any of the Information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit [www.ubs.com/disclosures](http://www.ubs.com/disclosures).

Research will initiate, update and cease coverage solely at the discretion of UBS Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on UBS Neo. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking, sales and trading are a part, and UBS's subsidiaries, branches and affiliates as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms under English law or, if not carried out by UBS in the UK the law of the relevant jurisdiction in which UBS determines it carries out the activity) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

Within the past 12 months UBS AG, its affiliates or subsidiaries may have received or provided investment services and activities or ancillary services as per MiFID II which may have given rise to a payment or promise of a payment in relation to these services from or to this company.

Where Global Research refers to "UBS Evidence Lab Inside" or has made use of data provided by UBS Evidence Lab you understand that UBS Evidence Lab is a separate department to Global Research and that UBS Evidence Lab does not provide research, investment recommendations or advice.

**United Kingdom:** This material is distributed by UBS AG, London Branch to persons who are eligible counterparties or professional clients. UBS AG, London Branch is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. **Europe:** Except as otherwise specified herein, these materials are distributed by UBS Europe SE, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients (as detailed in the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) Rules and according to MiFID) and are only available to such persons. The information does not apply to, and should not be relied upon by, retail clients. UBS Europe SE is authorised by the [European Central Bank (ECB)] and regulated by the BaFin and the ECB. **France:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Securities France S.A. UBS Securities France S.A. is regulated by the ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. **Germany, Luxembourg, the Netherlands, Belgium and Ireland:** Prepared by UBS AG, London Branch and distributed by UBS AG, London Branch and UBS Europe SE. **Spain:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:** Distributed by UBS AG, London Branch. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG, London Branch is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. **Poland:** Distributed by UBS Europe SE (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Europe SE (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce. **Russia:** Prepared and distributed by UBS Bank (OOO). **Switzerland:** Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). **Italy:** Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, Italy Branch. **South Africa:** Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). **Israel:** This material is distributed by UBS AG, London Branch. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS AG, London Branch and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS AG, London Branch is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS AG, London Branch and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons. **Saudi Arabia:** This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. **UAE / Dubai:** The information distributed by UBS AG Dubai Branch is only intended for Professional Clients and/or Market Counterparties, as classified under the DFSA rulebook. No other person should act upon this material/communication. The information is not for further distribution within the United Arab Emirates. UBS AG Dubai Branch is regulated by the DFSA in the DIFC. UBS is not licensed to provide banking services in the UAE by the Central Bank of the UAE, nor is it licensed by the UAE Securities and Commodities Authority. **United States:** Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate') to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule. **Canada:** Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. **Mexico:** This report has been distributed and prepared by UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is a subsidiary of UBS AG. This document is intended for distribution to institutional or sophisticated investors only. Research reports only reflect the views of the analysts responsible for the reports. Analysts do not receive any compensation from persons or entities different from UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, or different from entities belonging to the same financial group or business group of such. For Spanish translations of applicable disclosures, please go to [www.ubs.com/disclosures](http://www.ubs.com/disclosures). **Brazil:** Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM S.A. to persons who are eligible investors residing in Brazil, which are considered to be Investidores Profissionais, as designated by the applicable regulation, mainly the CVM Instruction No. 539 from the 13th of November 2013 (determines the duty to verify the suitability of products, services and transactions with regards to the client's profile). **Hong Kong:** Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch, which is incorporated in Switzerland with limited liability. Please contact local licensed/registered representatives of UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch in respect of any matters arising from, or in connection with, the analysis or document. **Singapore:** Distributed by UBS Securities Pte. Ltd. [MCI (P) 009/09/2018 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). **Japan:** Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. **Australia:** Clients of UBS AG: Distributed by UBS AG (ABN 47 088 129 613 and holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (ABN 62 008 586 481 and holder of Australian Financial Services License No. 231098). This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting



on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: [www.ubs.com/ecs-research-fsg](http://www.ubs.com/ecs-research-fsg).

**New Zealand:** Distributed by UBS New Zealand Ltd. UBS New Zealand Ltd is not a registered bank in New Zealand. You are being provided with this UBS publication or material because you have indicated to UBS that you are a "wholesale client" within the meaning of section 5C of the Financial Advisers Act 2008 of New Zealand (Permitted Client). This publication or material is not intended for clients who are not Permitted Clients (non-permitted Clients). If you are a non-permitted Client you must not rely on this publication or material. If despite this warning you nevertheless rely on this publication or material, you hereby (i) acknowledge that you may not rely on the content of this publication or material and that any recommendations or opinions in such this publication or material are not made or provided to you, and (ii) to the maximum extent permitted by law (a) indemnify UBS and its associates or related entities (and their respective Directors, officers, agents and Advisors) (each a 'Relevant Person') for any loss, damage, liability or claim any of them may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material and (b) waive any rights or remedies you may have against any Relevant Person for (or in respect of) any loss, damage, liability or claim you may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material. **Korea:** Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. This material is intended for professional/institutional clients only and not for distribution to any retail clients. **Malaysia:** This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. **India:** Distributed by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Number: INZ000259830; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: [http://www.ubs.com/global/en/about\\_ubs/investor\\_relations/annualreporting.html](http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html) **Taiwan:** Distributed by UBS Securities Pte. Ltd., Taipei Branch which is regulated by the Taiwan Securities and Futures Bureau. This document contains general information and/or general advice only and does NOT constitute any "Recommendation" to clients for the covered companies or any companies mentioned in this document. **Indonesia:** This report is being distributed by PT UBS Sekuritas Indonesia and is delivered by its licensed employee(s), including marketing/sales person, to its client. PT UBS Sekuritas Indonesia, having its registered office at Wisma GKB, 22nd floor, JL. Jend. Sudirman, kav.28, Jakarta 10210, Indonesia, is a subsidiary company of UBS AG and licensed under Capital Market Law no. 8 year 1995, a holder of broker-dealer and underwriter licenses issued by the Capital Market and Financial Institution Supervisory Agency (now Otoritas Jasa Keuangan/OJK). PT UBS Sekuritas Indonesia is also a member of Indonesia Stock Exchange and supervised by Otoritas Jasa Keuangan (OJK). Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens except in compliance with applicable Indonesian capital market laws and regulations. This report is not an offer of securities in Indonesia and may not be distributed within the territory of the Republic of Indonesia or to Indonesian citizens in circumstance which constitutes an offering within the meaning of Indonesian capital market laws and regulations.

The disclosures contained in research documents produced by UBS AG, London Branch or UBS Europe SE shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and in any event UBS accepts no liability whatsoever for any redistribution of this document or its contents or the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2020. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

## Global Wealth Management Disclaimer

You receive this document in your capacity as a client of UBS Global Wealth Management. This publication has been distributed to you by UBS Switzerland AG (regulated by FINMA in Switzerland) or its affiliates ("UBS") with whom you have a banking relationship with. The full name of the distributing affiliate and its competent authority can be found in the country-specific disclaimer at the end of this document.

The date and time of the first dissemination of this publication is the same as the date and time of its publication.

### Risk information:

You agree that you shall not copy, revise, amend, create a derivative work, provide to any third party, or in any way commercially exploit any UBS research, and that you shall not extract data from any research or estimates, without the prior written consent of UBS.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction.

This document is a general communication and is educational in nature; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. By providing this document, none of UBS or its representatives has any responsibility or authority to provide or have provided investment advice in a fiduciary capacity or otherwise. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. None of UBS or its representatives is suggesting that the recipient or any other person take a specific course of action or any action at all. By receiving this document, the recipient acknowledges and agrees with the intended purpose described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors.

Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the information (as defined below).

Prior to making any investment or financial decisions, any recipient of this document or the information should take steps to understand the risk and return of the investment and seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and circumstances of his or her investment objectives.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any materials to which this document relates (the "Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups, personnel or other representative of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances may this document or any of the Information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following purposes:



- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS (including between Global Wealth Management and Research) and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit [www.ubs.com/disclosures](http://www.ubs.com/disclosures).

Research will initiate, update and cease coverage solely at the discretion of research management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking, sales and trading are a part, and UBS's subsidiaries, branches and affiliates as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

Within the past 12 months UBS Switzerland AG, its affiliates or subsidiaries may have received or provided investment services and activities or ancillary services as per MiFID II which may have given rise to a payment or promise of a payment in relation to these services from or to this company.

If you require detailed information on disclosures of interest or conflict of interest as required by Market Abuse Regulation please contact the mailbox [MAR\\_disclosures\\_twopager@ubs.com](mailto:MAR_disclosures_twopager@ubs.com). Please note that e-mail communication is unsecured.

**External Asset Managers / External Financial Consultants:** In case this research or publication is provided to an External Asset Manager or an External Financial Consultant, UBS expressly prohibits that it is redistributed by the External Asset Manager or the External Financial Consultant and is made available to their clients and/or third parties.

Distributed to US persons by UBS Financial Services Inc. or UBS Securities LLC, subsidiaries of UBS AG. UBS Switzerland AG, UBS Europe SE, UBS Bank, S.A., UBS Brasil Administradora de Valores Mobiliarios Ltda, UBS Asesores Mexico, S.A. de C.V., UBS Securities Japan Co., Ltd, UBS Wealth Management Israel Ltd and UBS Menkul Degerler AS are affiliates of UBS AG. UBS Financial Services Incorporated of Puerto Rico is a subsidiary of UBS Financial Services Inc. **UBS Financial Services Inc. accepts responsibility for the content of a report prepared by a non-US affiliate when it distributes reports to US persons. All transactions by a US person in the securities mentioned in this report should be effected through a US-registered broker dealer affiliated with UBS, and not through a non-US affiliate. The contents of this report have not been and will not be approved by any securities or investment authority in the United States or elsewhere. UBS Financial Services Inc. is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule") and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule.**

**Austria:** This publication is not intended to constitute a public offer under Austrian law. It is distributed only for information purposes to clients of UBS Europe SE, Niederlassung Österreich, with place of business at Wächtergasse 1, A-1010 Wien. UBS Europe SE, Niederlassung Österreich is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Austrian Financial Market Authority (Finanzmarktaufsicht, FMA), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. **Bahrain:** UBS is a Swiss bank not licensed, supervised or regulated in Bahrain by the Central Bank of Bahrain and does not undertake banking or investment business activities in Bahrain. Therefore, clients have no protection under local banking and investment services laws and regulations. **Canada:** The information contained herein is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering, an offer to sell securities described herein, solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada or, alternatively, pursuant to a dealer registration exemption. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. In Canada, this publication is distributed by UBS Investment Management Canada Inc. **China:** This research report is neither intended to be distributed to PRC investors nor to provide securities investment consultancy services within the territory of PRC. **Czech Republic:** UBS is not a licensed bank in the Czech Republic and thus is not allowed to provide regulated banking or investment services in the Czech Republic. Please notify UBS if you do not wish to receive any further correspondence. **Denmark:** This publication is not intended to constitute a public offer under Danish law. It is distributed only for information purposes to clients of UBS Europe SE, Denmark Branch, filial af UBS Europe SE, with place of business at Sankt Annae Plads 13, 1250 Copenhagen, Denmark, registered with the Danish Commerce and Companies Agency, under No. 38 17 24 33. UBS Europe SE, Denmark Branch, filial af UBS Europe SE is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Danish Financial Supervisory Authority (Finanstilsynet), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. **Egypt:** Securities or other investment products are not being offered or sold by UBS to the public in Egypt and they have not been and will not be registered with the Egyptian Financial Supervisory Authority. **France:** This publication is distributed by UBS (France) S.A., French "société anonyme" with share capital of € 132.975.556, 69, boulevard Haussmann F-75008 Paris, R.C.S. Paris B 421 255 670, to its clients and prospects. UBS (France) S.A. is a provider of investment services duly authorized according to the terms of the "Code Monétaire et Financier", regulated by French banking and financial authorities as the "Autorité de Contrôle Prudentiel et de Résolution." **Germany:** This publication is not intended to constitute a public offer under German law. It is distributed only for information purposes to clients of UBS Europe SE, Germany, with place of business at Bockenheimer Landstrasse 2-4, 60306 Frankfurt am Main. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the European Central Bank ("ECB"), and supervised by the ECB, the German Central Bank (Deutsche Bundesbank) and the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), to which this publication has not been submitted for approval. **Greece:** UBS Switzerland AG and its affiliates (UBS) are not licensed as a bank or financial institution under Greek legislation and do not provide banking and financial services in Greece. Consequently, UBS provides such services from branches outside of Greece, only. This document may not be considered as a public offering made or to be made to residents of Greece. **Hong Kong:** This publication is distributed to clients of UBS AG Hong Kong Branch by UBS AG Hong Kong Branch, a licensed bank under the Hong Kong Banking Ordinance and a registered institution under the Securities and Futures Ordinance. UBS AG Hong Kong Branch is incorporated in Switzerland with limited liability. **Indonesia, Malaysia, Philippines, Thailand:** This material was provided to you as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the material erroneously, UBS asks that you kindly destroy/delete it and inform UBS immediately. Any and all advice provided and/or trades executed by UBS pursuant to the material will only have been provided upon your specific request or executed upon your specific instructions, as the case may be, and may be deemed as such by UBS and you. The

material may not have been reviewed, approved, disapproved or endorsed by any financial or regulatory authority in your jurisdiction. The relevant investments will be subject to restrictions and obligations on transfer as set forth in the material, and by receiving the material you undertake to comply fully with such restrictions and obligations. You should carefully study and ensure that you understand and exercise due care and discretion in considering your investment objective, risk appetite and personal circumstances against the risk of the investment. You are advised to seek independent professional advice in case of doubt. **India:** UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Number INZ000259830; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: [http://www.ubs.com/global/en/about\\_ubs/investor\\_relations/annualreporting.html](http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html). **Israel:** UBS is a premier global financial firm offering wealth management, asset management and investment banking services from its headquarters in Switzerland and its operations in over 50 countries worldwide to individual, corporate and institutional investors. In Israel, UBS Switzerland AG is registered as Foreign Dealer in cooperation with UBS Wealth Management Israel Ltd., a wholly owned UBS subsidiary. UBS Wealth Management Israel Ltd. is a Portfolio Manager licensee which engages also in Investment Marketing and is regulated by the Israel Securities Authority. This publication is intended for information only and is not intended as an offer to buy or solicitation of an offer. Furthermore, this publication is not intended as an investment advice and/or investment marketing and is not replacing any investment advice and/or investment marketing provided by the relevant licensee which is adjusted to each person needs. No action has been, or will be, taken in Israel that would permit an offering of the product(s) mentioned in this document or a distribution of this document to the public in Israel. In particular, this document has not been reviewed or approved by the Israeli Securities Authority. The product(s) mentioned in this document is/are being offered to a limited number of sophisticated investors who qualify as one of the investors listed in the first supplement to the Israeli Securities Law, 5728-1968. This document may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have been sent. Anyone who purchases the product(s) mentioned herein shall do so for its own benefit and for its own account and not with the aim or intention of distributing or offering the product(s) to other parties. Anyone who purchases the product(s) shall do so in accordance with its own understanding and discretion and after it has received any relevant financial, legal, business, tax or other advice or opinion required by it in connection with such purchase(s). The word "advice" and/or any of its derivatives shall be read and construed in conjunction with the definition of the term "investment marketing" as defined under the Israeli Regulation of Investment Advice, Investment Marketing and Portfolio Management Law, 1995. **Italy:** This publication is not intended to constitute a public offer under Italian law. It is distributed only for information purposes to clients of UBS Europe SE, Succursale Italia, with place of business at Via del Vecchio Politecnico, 3-20121 Milano. UBS Europe SE, Succursale Italia is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Bank of Italy (Banca d'Italia) and the Italian Financial Markets Supervisory Authority (CONSOB - Commissione Nazionale per le Società e la Borsa), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. **Jersey:** UBS AG, Jersey Branch, is regulated and authorized by the Jersey Financial Services Commission for the conduct of banking, funds and investment business. Where services are provided from outside Jersey, they will not be covered by the Jersey regulatory regime. UBS AG, Jersey Branch is a branch of UBS AG a public company limited by shares, incorporated in Switzerland whose registered offices are at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH 8001 Zurich. UBS AG, Jersey Branch's principal place business is 1, IFC Jersey, St Helier, Jersey, JE2 3BX. **Luxembourg:** This publication is not intended to constitute a public offer under Luxembourg law. It is distributed only for information purposes to clients of UBS Europe SE, Luxembourg Branch, with place of business at 33A, Avenue J. F. Kennedy, L-1855 Luxembourg. UBS Europe SE, Luxembourg Branch is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Luxembourg supervisory authority (Commission de Surveillance du Secteur Financier), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. **Mexico:** This information is distributed by UBS Asesores México, S.A. de C.V. ("UBS Asesores"), an affiliate of UBS Switzerland AG, incorporated as a non-independent investment advisor under the Securities Market Law due to the relation with a Foreign Bank. UBS Asesores is a regulated entity and it is subject to the supervision of the Mexican Banking and Securities Commission ("CNBV"), which exclusively regulates UBS Asesores regarding the rendering of portfolio management, as well as on securities investment advisory services, analysis and issuance of individual investment recommendations, so that the CNBV has no surveillance faculties nor may have over any other service provided by UBS Asesores. UBS Asesores is registered before CNBV under Registry number 30060. You are being provided with this UBS publication or material because you have indicated to UBS Asesores that you are a Sophisticated Qualified Investor located in Mexico. The compensation of the analyst(s) who prepared this report is determined exclusively by research management and senior management of any entity of UBS Group to which such analyst(s) render services. **Nigeria:** UBS Switzerland AG and its affiliates (UBS) are not licensed, supervised or regulated in Nigeria by the Central Bank of Nigeria or the Nigerian Securities and Exchange Commission (SEC) and do not undertake banking or investment business activities in Nigeria. The investment products mentioned in this material are not being offered or sold by UBS to the public in Nigeria and they have not been submitted for approval nor registered with the Nigerian SEC. If you are interested in products of this nature, please let us know and we will direct you to someone who can advise you. The investment products mentioned in this material are not being directed to, and are not being made available for subscription by any persons within Nigeria other than the selected investors to whom the offer materials have been addressed as a private sale or domestic concern within the exemption and meaning of Section 69(2) of the Investments and Securities Act, 2007 (ISA). **Portugal:** UBS Switzerland AG is not licensed to conduct banking and financial activities in Portugal nor is UBS Switzerland AG supervised by the Portuguese regulators (Bank of Portugal "Banco de Portugal" and Portuguese Securities Exchange Commission "Comissão do Mercado de Valores Mobiliários"). **Russia:** This document or information contained therein is for information purposes only and constitute neither a public nor a private offering, is not an invitation to make offers, to sell, exchange or otherwise transfer any financial instruments in the Russian Federation to or for the benefit of any Russian person or entity and does not constitute an advertisement or offering of securities in the Russian Federation within the meaning of Russian securities laws. **Singapore:** This material was provided to you as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the material erroneously, UBS asks that you kindly destroy/delete it and inform UBS immediately. Clients of UBS AG Singapore branch are asked to please contact UBS AG Singapore branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or report. **Spain:** This publication is not intended to constitute a public offer under Spanish law. It is distributed only for information purposes to clients of UBS Europe SE, Sucursal en España, with place of business at Calle María de Molina 4, C.P. 28006, Madrid. UBS Europe SE, Sucursal en España is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Spanish supervisory authority (Banco de España), to which this publication has not been submitted for approval. Additionally it is authorized to provide investment services on securities and financial instruments, regarding which it is supervised by the Comisión Nacional del Mercado de Valores as well. UBS Europe SE, Sucursal en España is a branch of UBS Europe SE, a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. **Sweden:** This publication is not intended to constitute a public offer under Swedish law. It is distributed only for information purposes to clients of UBS Europe SE, Sweden Bankfilial, with place of business at Regeringsgatan 38, 11153 Stockholm, Sweden, registered with the Swedish Companies Registration Office under Reg. No 516406-1011. UBS Europe SE, Sweden Bankfilial is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Swedish supervisory authority (Finansinspektionen), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. **Taiwan:** This material is provided by UBS AG, Taipei Branch in accordance with laws of Taiwan, in agreement with or at the request of clients/prospects. **Turkey:** No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey in the Republic of Turkey. UBS Switzerland AG is not licensed by the Turkish Capital Market Board (the CMB) under the provisions of the Capital Market Law (Law No. 6362). Accordingly neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the CMB. However, according to article 15 (d) (ii) of the Decree No. 32 there is no restriction on the purchase or sale of the instruments by residents of the Republic of Turkey. **UAE:** UBS is not licensed in the UAE by the Central Bank of UAE or by the Securities & Commodities Authority. The UBS AG Dubai Branch is licensed in the DIFC by the Dubai Financial Services Authority as an authorised firm. **United Kingdom:** This document is issued by UBS Wealth Management, a division of UBS AG which is authorised and regulated by the Financial Market Supervisory Authority in Switzerland. In the United Kingdom, UBS AG is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of regulation by the Prudential Regulation Authority are available from us on request. A member of the London Stock Exchange. This publication is distributed to retail clients of UBS Wealth Management. **Ukraine:** UBS is not registered and licensed as a bank/financial institution under Ukrainian legislation and does not provide banking and other financial services in Ukraine. UBS has not made and will not make any offer of the mentioned products to the public in Ukraine. No action has been taken to authorize an offer of the mentioned products to the public in Ukraine and the distribution of this document shall not constitute financial services for the purposes of the Law of Ukraine "On Financial Services and State Regulation of Financial Services Markets" dated 12 July 2001. Accordingly, nothing in this document or any other document, information or communication related to the mentioned products

shall be interpreted as containing an offer or invitation to offer, or solicitation of securities in the territory of Ukraine. Electronic communication must not be considered as an offer to enter into an electronic agreement or electronic instrument within the meaning of the Law of Ukraine "On Electronic Commerce" dated 3 September 2015.

**This document is strictly for private use by its holder and may not be passed on to third parties or otherwise publicly distributed.**

© UBS 2020. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.



## 尖峰报告社群

分享8万+行业报告/案例、7000+工具/模版；  
精选各行业前沿数据、经典案例、职场干货等。



截屏本页，微信扫一扫或搜索公众号“尖峰报告”  
回复<进群> 即刻加入